Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Mohamed M. G. Mohamed; Safia Shaikh; Mohammed Osman; Babikir Kheiri

doi:10.1055/a-1827-8128

TH Open, Inhaltsverzeichnis

CC BY 4.0 · TH Open 2022; 06(02): e144-e146
DOI: 10.1055/a-1827-8128

Letter to the Editor

Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Mohamed M. G. Mohamed

¹Internal Medicine Department, SSM Health St. Mary's Hospital, St. Louis, Missouri, United States

,

Safia Shaikh

¹Internal Medicine Department, SSM Health St. Mary's Hospital, St. Louis, Missouri, United States

,

Mohammed Osman

²Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon, United States

,

Babikir Kheiri

²Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon, United States

References
1 Collet JP, Thiele H, Barbato E. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42 (14) 1289-1367
2 Bagai A, Peterson ED, Honeycutt E. et al. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care 2015; 4 (06) 499-508
3 Kheiri B, Osman M, Abdalla A. et al. De-escalation of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials. J Cardiovasc Pharmacol Ther 2019; 24 (02) 153-159
4 Kim CJ, Park MW, Kim MC. et al; TALOS-AMI investigators. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet 2021; 398 (10308): 1305-1316
5 Ueno T, Koiwaya H, Sasaki KI. et al. Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting. Cardiovasc Interv Ther 2017; 32 (04) 341-350
6 Cuisset T, Deharo P, Quilici J. et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017; 38 (41) 3070-3078
7 Claassens DMF, Vos GJA, Bergmeijer TO. et al. A genotype-guided strategy for oral P2Y₁₂ inhibitors in primary PCI. N Engl J Med 2019; 381 (17) 1621-1631
8 Mehran R, Baber U, Sharma SK. et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019; 381 (21) 2032-2042
9 Levine GN, Jeong YH, Goto S. et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014; 11 (10) 597-606
10 Kupka D, Sibbing D. De-escalation of P2Y12 receptor inhibitor therapy after acute coronary syndromes in patients undergoing percutaneous coronary intervention. Korean Circ J 2018; 48 (10) 863-872